Concerns about pneumonia mortality and increased pneumonia prevalence are driving the market growth
One of the main factors anticipated to drive the growth of the market CAGR is the notable increase in the prevalence of pneumonia worldwide. Pneumonia is generally more common in the elderly and pediatric populations. For instance, according to a 2019 United Nations International Children's Emergency Fund (UNICEF) article, there are more than 1,400 instances of pneumonia worldwide for every 100,000 people. Additionally, with 2,500 instances and 1,620 cases per 100,000 children, respectively, South Asia and West and Central Africa had the highest incidences of it. As a result, the aforementioned variables are significant market growth drivers.
Among all infectious diseases, pneumonia is regarded as one of the most frequent causes of hospitalization. If the patient is determined to be critically ill, additional microbiological testing for pneumonia is performed while the patient is hospitalized. For instance, according to estimates from the American Thoracic Society (ATS), each year, approximately 1.0 million adult Americans seek hospital care as a result of pneumonia. Guidelines for Community-Acquired Pneumonia (CAP) were released by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) since developed countries are also increasingly concerned about pneumonia testing.
It is anticipated that developing countries will follow these standards for pneumonia testing in order to raise awareness of the testing protocols. Therefore, the variables listed above are important catalysts for the expansion of the market throughout the anticipated period.
Pneumonia testing market developments over time have included a change in consumer preferences and a rise in the demand for point-of-care diagnostics. Rapid diagnostic tools are desperately needed since pneumonia is becoming more common. The point-of-care testing segment is becoming popular among patients and healthcare professionals due to its main advantages, which include convenience, faster diagnosis times, and better treatment outcomes. As per a January 2020 NCBI post, quick syndromic molecular testing for pneumonia provide more accurate diagnosis than the present gold standard of culture.
The study indicated that commercially available syndromic diagnostic testing platforms, such as Unyvero and Filmarray Pneumonia panel, are more effective at detecting pneumonia than a traditional diagnostic technique.
The pneumonia testing market is growing thanks to the development of new, more precise, sensitive, and targeted testing techniques. Point-of-care (POC) testing is being used more often to identify pneumonia due to its increased efficacy and quick turnaround time for test results. The more sophisticated multiplex PCR (mPCR)-based pneumonia testing technology offers improved detection efficiency at a lower cost and in less time. Additionally, the use of antibiotics in the past had no effect on the DNA or RNA replication of minuscule microbes because it does not require live microorganisms.
Point-of-care testing is, therefore, being driven by the increased prevalence of chronic diseases among a broad consumer base that is adopting quick, affordable diagnostic testing. The POC test's ability to provide quick and precise results contributes to the advancement of patient-centered healthcare in bedside settings, which in turn encourages the use of point-of-care testing and, ultimately, the expansion of the pneumonia testing market. Thus, driving the pneumonia testing market revenue.
The increasing prevalence of pneumonia, coupled with advancements in diagnostic technologies, suggests a growing demand for effective pneumonia testing solutions.
Centers for Disease Control and Prevention (CDC)